Evidence map›Paper›PMID 41208941›Full record

ArticleResearch and practice in thrombosis and haemostasis2025

Von Willebrand disease diagnosis: from complexity to simplicity.

Quentin Van Thillo, Cédric Hermans

Abstract readEditorial
In one paragraph

Article in Research and practice in thrombosis and haemostasis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Quentin Van ThilloHaemophilia Centre, Department of Cardiovascular Diseases, University Hospitals Leuven, Leuven, Belgium.
Cédric HermansThrombosis and Haemostasis unit, Division of Haematology, Cliniques universitaires Saint-Luc, Université catholique de Louvain (UCLouvain), Brussels, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Von Willebrand disease (VWD) is a complex disorder in terms of both its pathophysiology and treatment. The broad recognition and treatment of patients with VWD is often hindered by the complicated diagnostic process. Therefore, a more streamlined approach is needed, particularly in settings with limited expertise or resources. One practical initial strategy is to prioritize measuring von Willebrand factor (VWF) activity using a robust assay, alongside VWF antigen and factor (F)VIII levels, and administering a test dose of desmopressin. Once a diagnosis has been established, 3 variables should be considered for patients requiring replacement therapy: the patient's endogenous VWF activity and FVIII levels, and the quality of the infused multimers, as reflected by the VWF activity/antigen ratio of the concentrate. This simplified framework can facilitate the global diagnosis and management of VWD patients. However, we acknowledge the limitations, particularly with regard to accurately subtyping patients with type 2 VWD, since precise classification is essential for optimal care.

Indexed as

diagnosisfactor VIIImultimeric proteinsVon Willebrand diseasesvon Willebrand factor

Identifiers

PMID41208941
PMCPMC12590420

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.